MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.320
+0.090
+2.79%
After Hours: 3.320 0 0.00% 16:12 07/07 EDT
OPEN
3.220
PREV CLOSE
3.230
HIGH
3.360
LOW
3.120
VOLUME
592.13K
TURNOVER
--
52 WEEK HIGH
6.04
52 WEEK LOW
1.600
MARKET CAP
173.70M
P/E (TTM)
-7.8210
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PIRS stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 5.00.

EPS

PIRS News

More
Is Pieris Pharmaceuticals, Inc. (PIRS) A Good Stock To Buy?
Insider Monkey · 06/23 16:51
Edited Transcript of PIRS earnings conference call or presentation 11-May-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/08 18:28
Earnings Update: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Just Reported And Analysts Are Boosting Their Estimates
Simply Wall St. · 05/14 15:23
Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/11 18:29
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 05/11 14:55
Pieris Pharmaceuticals: Q1 Earnings Insights
Benzinga · 05/11 12:28
Pieris Pharmaceuticals Q1 EPS $(0.07) Beats $(0.17) Estimate, Sales $13.261M Beat $8.840M Estimate
Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.070) per share which beat the analyst consensus estimate of $(0.170) by 58.82 percent. This is a 65 percent increase over losses of $(0.200) per share
Benzinga · 05/11 11:45
Pieris Pharmaceuticals: Q1 Earnings Insights
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected at $2.91 after the company reported Q1 results. Quarterly Results Earnings per share rose 65.00% year over year to ($0.07), which beat the estimate of ($0.17).
Benzinga · 05/11 11:28

Industry

Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About PIRS

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
More

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.